Award
NIH Reporter #5U24HL148563-06
2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial
Recipient
Theron C Casper
Award Amount
$600,839.00
Ceiling
$600,839.00
Awarded
August 20, 2025
Identifier
5U24HL148563-06
This award funds a clinical trial to evaluate arginine therapy for managing pain in children with sickle cell disease, focusing on efficacy, safety, and biochemical effects.
Description
A phase 3 randomized, placebo-controlled clinical trial investigating the safety and efficacy of arginine therapy for sickle cell disease (SCD) pain management. The project aims to determine the efficacy of IV arginine therapy on time-to-crisis resolution, opioid use, and pain scores in children with SCD and VOE, monitor safety, and characterize biochemical and mitochondrial changes.